The year 2024 continues to see significant mergers and acquisitions (M&A) activity in the biopharma sector.
Here's a breakdown of 17 major deals announced in late 2023/early 2024, including acquisition prices and key details. 👇
Mirati Therapeutics
Acquired By: Bristol-Myers Squibb
Acquisition Date (Closed): Jan. 23, 2024
Acquisition Price: $4.8B
ImmunoGen
Acquired By: AbbVie
Acquisition Date (Closed): Feb. 12, 2024
Acquisition Price: $10.1B
Icosavax
Acquired By: AstraZeneca (AZN)
Acquisition Date (Closed): Feb. 19, 2024
Acquisition Price: $1.1B
Karuna Therapeutics
Acquired By: Bristol-Myers Squibb
Acquisition Date (Closed): Mar. 18, 2024
Acquisition Price: $14B
RayzeBio
Acquired By: Bristol-Myers Squibb
Acquisition Date (Closed): Feb. 26, 2024
Acquisition Price: $4.1B
Gracell Biotechnologies
Acquired By: AstraZeneca (AZN)
Acquisition Date (Closed): Feb. 22, 2024
Acquisition Price: $1.2B
Ambrx Biopharma
Acquired By: Johnson & Johnson
Announcement Date: Jan. 8, 2024
Acquisition Price: $2B
Acquisition Date (Closed): Mar. 7, 2024
Harpoon Therapeutics
Acquired By: Merck
Acquisition Date (Closed): Mar. 11, 2024
Acquisition Price: $680M
Aiolos Bio
Acquired By: GSK
Announcement Date: Jan 9, 2024
Acquisition Price: $1B
Acquisition Date (Closed): Feb. 15, 2024
Inhibrx
Acquired By: Sanofi
Announcement Date: Jan. 23, 2024
Acquisition Price: $1.7B
Acquisition Date (Closed): Pending
Lead Asset: INBRX-101
Stage: Phase 2
Indication: Severe alpha-1 antitrypsin deficiency (PiZZ)
Morphosys
Acquired By: Novartis
Announcement Date: Jan. 5, 2024
Acquisition Price: $2.9B
Acquisition Date (Closed): Pending
Lead Asset: Monjuvi (Tafasitamab)
Stage: Approved
Indication: Various Cancers
Catalent
Acquired By: Novo Holdings
Announcement Date: Jan. 5, 2024
Acquisition Price: $16.5B
Acquisition Date (Closed): Pending
Cymabay Therapeutics
Acquired By: Gilead Sciences
Announcement Date: Feb. 12, 2024
Acquisition Price: $4.3B
Acquisition Date (Closed): Mar. 22, 2024
Amolyt Pharma
Acquired By: AstraZeneca
Announcement Date: Mar. 14, 2024
Acquisition Price: $1.05B
Acquisition Date (Closed): Pending
Lead Asset: Eneboparatide (AZP-3601)
Stage: Phase 3
Indication: Hypoparathyroidism
Fusion Pharmaceuticals
Acquired By: AstraZeneca
Announcement Date: Mar. 19, 202
Acquisition Price: $2.4B
Acquisition Date (Closed): Pending
Lead Asset: FPI-2265
Stage: Phase 2/3
Indication: Prostate cancer
Shockwave Medical
Acquired By: Johnson & Johnson
Announcement Date: Jan. 23, 2024
Acquisition Price: $13.1B
Acquisition Date (Closed): Pending
Alpine Immune Sciences
Acquired By: Vertex Pharmaceuticals
Announcement Date: Apr. 10, 2024
Acquisition Price: $4.9B
Acquisition Date (Closed): Pending
Lead Asset: Povetacicept (ALPN-303)
Stage: IgA nephropathy
Indication: Phase 3
Figure 1. Biopharma M&A Activity (late 2023/early 2024).
---
Get a list of all recently funded companies with deeper info to help your sales/BD activities. Contact us to learn more
Article History:
RF, DV (04/20/24)
This article is not investment or legal advice.
Comments